Начало › Хронична лимфоцитна левкемия › Северна Каролина › Durham
Клинични проучвания за Хронична лимфоцитна левкемия в Durham, NC
27 проучвания за Хронична лимфоцитна левкемия търсят участници в обекти в и около Durham (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Durham VA Medical Center, Durham
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Набиране на участнициФаза 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
- University of North Carolina-Hillsborough Campus, Hillsborough · на 13 мили
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Набиране на участнициФаза 3
- University of North Carolina At Chapel Hill, Chapel Hill · на 10 мили
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Набиране на участнициФаза 3
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · на 10 мили
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Набиране на участнициФаза 3
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Набиране на участнициФаза 2
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Набиране на участнициФаза 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Набиране на участнициФаза 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · на 10 мили
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Набиране на участнициФаза 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · на 10 мили
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Набиране на участнициФаза 2
- Research Site, Durham
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Набиране на участнициФаза 1
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Набиране на участнициФаза 1
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Набиране на участници
- North Carolina Basnight Cancer Hospital, Chapel Hill · на 10 мили
Registry of Older Patients With Cancer
Набиране на участнициНаблюдателно проучване
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 мили
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Набиране на участнициФаза 1
- University of North Carolina, Chapel Hill · на 10 мили
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Набиране на участнициФаза 4
- Duke University Medical Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Набиране на участнициФаза 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
Набиране на участнициФаза 1
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Набиране на участнициФаза 2
- University of North Carolina /ID# 233313, Chapel Hill · на 10 мили
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Набиране на участнициФаза 2
- The University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Набиране на участнициФаза 1
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Набиране на участнициНаблюдателно проучване
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · на 10 мили
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Набиране на участнициФаза 2
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Набиране на участнициФаза 1
- University of North Carolina, Chapel Hill · на 10 мили
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Набиране на участнициФаза 1
- Duke University, Durham
Проучвания за Хронична лимфоцитна левкемия в други градове
- Boston, MA31 проучвания
- Columbus, OH28 проучвания
- Washington, DC22 проучвания
- Seattle, WA20 проучвания
- Rochester, MN19 проучвания
- New York City, NY18 проучвания
- Houston, TX17 проучвания
- Baldwin Park, CA16 проучвания
- Milwaukee, WI15 проучвания
- Chicago, IL14 проучвания
- Cincinnati, OH14 проучвания
- Nashville, TN13 проучвания
Други проучвания в Durham
- Рак на гърдата63 проучвания
- Рак (всички видове)58 проучвания
- Рак на белия дроб с недребноклетъчен тип39 проучвания
- Множествен миелом37 проучвания
- Метастатичен рак33 проучвания
- Остра миелоидна левкемия33 проучвания
- Рак на белия дроб32 проучвания
- Рак на простатата32 проучвания
- Колоректален рак28 проучвания
- Рак на яйчниците27 проучвания
- Сърдечна недостатъчност26 проучвания
- Рак на панкреаса24 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.